Pathos AI licenses first-in-class bispecific ADC JSKN016 from Alphamab Oncology in deal worth up to $4.8 billion

Pathos AI licenses first-in-class bispecific ADC JSKN016 from Alphamab Oncology in deal worth up to $4.8 billion

Pathos AI has entered a global licensing agreement with Alphamab Oncology for JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC), paying $200 million upfront in a deal that could be worth up to $4.8 billion if development, regulatory and commercial milestones are achieved.

The transaction adds a differentiated clinical-stage oncology asset to Pathos AI's pipeline while enabling Alphamab Oncology to retain Greater China rights and participate in the programme's long-term commercial success through milestone payments and royalties.

Field	Content
Alert Type	Deal
Companies	Pathos AI; Alphamab Oncology
Deal Type	Global licensing agreement
Asset or Company	JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC)
Therapy Area(s)	Oncology; Solid tumours
Technology or Modality	Bispecific antibody-drug conjugate (ADC)
Deal Value	$200 million upfront, with potential development, regulatory and commercial milestone payments bringing the total value to up to $4.8 billion, plus tiered royalties on future net sales.
Development Stage	Phase I/II
Geography	Global excluding Greater China (Alphamab Oncology retains Greater China rights)
What Happened	On 5 August 2026, Pathos AI announced a global licensing agreement with Alphamab Oncology for exclusive rights outside Greater China to develop, manufacture and commercialise JSKN016. Pathos AI will pay $200 million upfront and may make additional milestone payments of up to $4.6 billion, together with tiered royalties on net sales. Alphamab Oncology retains rights in Greater China while both companies will collaborate on technology transfer and ongoing development activities.
Why It Matters	The agreement provides Pathos AI with a clinical-stage bispecific ADC targeting both TROP2 and HER3, expanding its precision oncology portfolio with a novel modality that could have potential across multiple solid tumours. For Alphamab Oncology, the partnership provides significant non-dilutive capital while retaining regional commercial rights and future economic participation outside Greater China.
Supporting Context	JSKN016 is designed to target both TROP2 and HER3, two proteins frequently expressed across a range of epithelial cancers. Early clinical studies are evaluating the candidate in patients with advanced solid tumours, where bispecific ADCs are being explored as a strategy to improve tumour targeting while broadening therapeutic activity.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com